Newron Points ‘Future Value-Driver’ Evenamide At Drug-Resistant Schizophrenia

Following Phase II Promise

One head split into two faces, one red and one blue, representing concept of schizophrenia
Schizophrenia Affects Around 24 Million People Worldwide • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D